Maintenance. We are currently updating the site. Please check back shortly
Members login
  • TrustLaw
  • Members Portal
Subscribe

U.S. FDA warns of flu protection claims by supplement sellers

Source: Thomson Reuters Foundation - Fri, 15 Feb 2013 07:09 PM
Author: Reuters
hum-dis
Tweet Recommend Google + LinkedIn Bookmark Email Print
Leave us a comment

(Updates with comment from FDA official)

By Toni Clarke

Feb 15 (Reuters) - U.S. health regulators have sent letters to nine Internet distributors of dietary supplements warning them against making false claims about their products' ability to fight the flu.

The U.S. Food and Drug Administration posted the letters on its website late Thursday in an effort to steer consumers away from a variety of herbal products that the distributors claim reduce the duration or severity of the flu.

In a letter to a company called Supplementality LLC, for example, FDA said the distributor was improperly offering products intended to diagnose, mitigate, prevent, treat or cure the flu virus, and demanded the company "immediately cease marketing" in this way.

"There are no over-the-counter products that shorten the duration or severity of the flu," Gary Coody, FDA's national health fraud coordinator, said in an interview.

The warning covers products including Resveratrol, Garlic, Echinacea, Elderberry, Ashwagandha and Astragalus Immune System Support.

The warning letters come amid an unusually severe cold and flu season, which has pushed up demand for cold remedies.

Coody said that in some cases the infractions cited in the warning letters related to misleading claims about the supplements. In other cases they related to the sale of fake versions of the prescription antiviral drug Tamiflu.

Other companies that received warning letters include Discount Online Pharmacy, Kosher Vitamin Express, Medsnoscript, Oasis Consumer Healthcare LLC, Secure Medical Inc, Sun Drug Store, Vitalmax Vitamins, and University of Berkley, whose marketing of the "Berkley-Body-Immune Flu Prevention" product violates the law.

Coody said six companies have made corrections following their receipt of the letters, which were issued earlier this month.

(Reporting By Toni Clarke in Washington; editing by Nick Zieminski and Matthew Lewis)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus
TOPICAL CONTENT
Topical content
LATEST SLIDESHOW

Latest slideshow

See allSee all
FEATURED JOBS
Featured jobs